Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19), primarily infects the respiratory and digestive tract. Several studies have indicated the alterations of the bacteria...

Full description

Bibliographic Details
Main Authors: Linlin Xie, Liangjun Chen, Xinran Li, Junying Zhou, Hongpan Tian, Jin Zhao, Zhiqiang Li, Yirong Li
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Pathogens
Subjects:
Online Access:https://www.mdpi.com/2076-0817/12/7/944
_version_ 1797587879974666240
author Linlin Xie
Liangjun Chen
Xinran Li
Junying Zhou
Hongpan Tian
Jin Zhao
Zhiqiang Li
Yirong Li
author_facet Linlin Xie
Liangjun Chen
Xinran Li
Junying Zhou
Hongpan Tian
Jin Zhao
Zhiqiang Li
Yirong Li
author_sort Linlin Xie
collection DOAJ
description Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19), primarily infects the respiratory and digestive tract. Several studies have indicated the alterations of the bacterial microbiome in the lower respiratory tract during viral infection. However, both bacterial and fungal microbiota in the lung of COVID-19 patients remained to be explored. Methods: In this study, we conducted nanopore sequencing analyses of the lower respiratory tract samples from 38 COVID-19 patients and 26 non-COVID-19 pneumonia controls. Both bacterial and fungal microbiome diversities and microbiota abundances in the lung were compared. Results: Our results revealed significant differences in lung microbiome between COVID-19 patients and non-COVID-19 controls, which were strongly associated with SARS-CoV-2 infection and clinical status. COVID-19 patients exhibited a notably higher abundance of opportunistic pathogens, particularly <i>Acinetobacter baumannii</i> and <i>Candida</i> spp. Furthermore, the potential pathogens enriched in COVID-19 patients were positively correlated with inflammation indicators. Conclusions: Our study highlights the differences in lung microbiome diversity and composition between COVID-19 patients and non-COVID-19 patients. This may contribute to predicting co-pathogens and selecting optimal treatments for respiratory infections caused by SARS-CoV-2.
first_indexed 2024-03-11T00:45:05Z
format Article
id doaj.art-9b11a4fb55bf4244a0a10e522b622289
institution Directory Open Access Journal
issn 2076-0817
language English
last_indexed 2024-03-11T00:45:05Z
publishDate 2023-07-01
publisher MDPI AG
record_format Article
series Pathogens
spelling doaj.art-9b11a4fb55bf4244a0a10e522b6222892023-11-18T20:51:16ZengMDPI AGPathogens2076-08172023-07-0112794410.3390/pathogens12070944Analysis of Lung Microbiome in COVID-19 Patients during Time of HospitalizationLinlin Xie0Liangjun Chen1Xinran Li2Junying Zhou3Hongpan Tian4Jin Zhao5Zhiqiang Li6Yirong Li7Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, ChinaBackground: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19), primarily infects the respiratory and digestive tract. Several studies have indicated the alterations of the bacterial microbiome in the lower respiratory tract during viral infection. However, both bacterial and fungal microbiota in the lung of COVID-19 patients remained to be explored. Methods: In this study, we conducted nanopore sequencing analyses of the lower respiratory tract samples from 38 COVID-19 patients and 26 non-COVID-19 pneumonia controls. Both bacterial and fungal microbiome diversities and microbiota abundances in the lung were compared. Results: Our results revealed significant differences in lung microbiome between COVID-19 patients and non-COVID-19 controls, which were strongly associated with SARS-CoV-2 infection and clinical status. COVID-19 patients exhibited a notably higher abundance of opportunistic pathogens, particularly <i>Acinetobacter baumannii</i> and <i>Candida</i> spp. Furthermore, the potential pathogens enriched in COVID-19 patients were positively correlated with inflammation indicators. Conclusions: Our study highlights the differences in lung microbiome diversity and composition between COVID-19 patients and non-COVID-19 patients. This may contribute to predicting co-pathogens and selecting optimal treatments for respiratory infections caused by SARS-CoV-2.https://www.mdpi.com/2076-0817/12/7/944COVID-19SARS-CoV-2lung microbiotananopore sequencing
spellingShingle Linlin Xie
Liangjun Chen
Xinran Li
Junying Zhou
Hongpan Tian
Jin Zhao
Zhiqiang Li
Yirong Li
Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
Pathogens
COVID-19
SARS-CoV-2
lung microbiota
nanopore sequencing
title Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
title_full Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
title_fullStr Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
title_full_unstemmed Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
title_short Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization
title_sort analysis of lung microbiome in covid 19 patients during time of hospitalization
topic COVID-19
SARS-CoV-2
lung microbiota
nanopore sequencing
url https://www.mdpi.com/2076-0817/12/7/944
work_keys_str_mv AT linlinxie analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT liangjunchen analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT xinranli analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT junyingzhou analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT hongpantian analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT jinzhao analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT zhiqiangli analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization
AT yirongli analysisoflungmicrobiomeincovid19patientsduringtimeofhospitalization